ArticleAdvances in therapy2026
Patient and Healthcare Professional Attitudes and Trial Experiences with a Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) for Schizophrenia Treatment.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05693935 (A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong-acting injectable (LAI) antipsychotics improve schizophrenia treatment adherence compared with oral antipsychotics but remain underused. TV-44749 is an innovative, once-monthly, subcutaneous (SC) LAI olanzapine designed to provide sustained efficacy through controlled olanzapine release over the monthly dosing interval without oral supplementation or complex initiation regimens. This survey assessed patients' and healthcare professionals' (HCPs) attitudes and experiences with TV-44749 during the phase 3 SOLARIS trial.
methodsThis study complemented the SOLARIS trial, which assessed the efficacy, safety, and tolerability of TV-44749 in adults with schizophrenia (NCT05693935). Separate online surveys were developed and sent to patients and HCPs.
resultsOverall, 70 patients (66% male; mean [SD] age, 44 [10.7] years) and 35 HCPs (11 physicians and 24 nurses) completed the survey. Patient characteristics mirrored the larger SOLARIS population. Patients preferred SC versus intramuscular injections (79% vs. 21%, respectively), primarily due to the shorter/thinner needle (67%). For HCPs, injection route preference was balanced. Most patients (90%) indicated that an LAI without a post-injection monitoring period would be helpful. Most physicians (> 90%) and nurses (> 66%) reported that the post-injection monitoring requirements present potential treatment barriers and clinical challenges that could impact LAI use. Most respondents (> 81%) indicated that injection type, initiation regimen, and dosing schedule were important treatment attributes. Patients attributed a higher degree of value than HCPs to dosing schedule and injection type. Respondents (> 72%) had favorable responses (satisfied or very satisfied) regarding TV-44749's initiation regimen, dosing schedule, and the trial medication overall, and answered favorably regarding continuing TV-44749 treatment.
conclusionOverall, this study highlights the differential value of TV-44749 and where it may address barriers associated with IM LAI olanzapine pamoate use. Additionally, these results provide insight into differences in attitudes and experiences among patients and HCPs regarding use of LAIs and help to identify opportunities where education could improve LAI adoption. Graphical plain language summary available for this article.
Indexed as
Identifiers
42742891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.